Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Waldo Ortuzar Feliu"'
Autor:
Andrea Bullock, Justin Moser, Daruka Mahadevan, Michael Gordon, Przemyslaw Twardowski, Apostolia Tsimberidou, Breelyn Wilky, Waldo Ortuzar Feliu, Anthony El-Khoueiry, Steven O’Day, Bruno Bockorny, Katherine Rosenthal
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/e5ddc153157d45b0bd1cab923730850e
Autor:
Hong Zhang, Robert Wesolowski, Cesar Perez, Breelyn Wilky, Waldo Ortuzar Feliu, Remigiusz Kaleta, Jonathan Trent
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/d9efd596b15243f99e0eff9a0bab8841
Autor:
Isabelle Ray-Coquard, Jerome Alexandre, Waldo Ortuzar Feliu, Remigiusz Kaleta, David O’Malley, Michael O’Neal, Julie Cole, Robert Ludwig, Madhavi Nallewar, Victoria Borisovskaya
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/26daa2815f004fa1931d2e022cd5f182
Autor:
David M. O'Malley, Maryna Neffa, Bradley J. Monk, Tamar Melkadze, Marilyn Huang, Anna Kryzhanivska, Iurie Bulat, Tarek M. Meniawy, Andrea Bagameri, Edward W. Wang, Bernard Doger de Speville Uribe, Roberto Hegg, Waldo Ortuzar Feliu, Marek Ancukiewicz, Iwona Lugowska
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(7)
PURPOSE Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte–associated antigen-4) are two new checkpoint inhibitors emerging as promising investigational agents for the treatment of advanced cervical cancer. This phase
Autor:
Kathleen N. Moore, Alexandra Leary, Dominique Berton, Christina P. Opperman, Maria Del Pilar Estevez-Diz, Laurence Gladieff, Marek Ancukiewicz, Anne-Claire Hardy-Bessard, Frédéric Selle, Isabelle Ray-Coquard, Waldo Ortuzar Feliu, Carlos Rojas, Bradley J. Monk, David M. O'Malley, Ana Oaknin, Carla Rameri Alexandre Silva de Azevedo, Leslie M Randall, Jérôme Alexandre
Publikováno v:
Scientia
Cervical cancer; Checkpoint inhibitor; Immunotherapy Cáncer de cuello uterino; Inhibidor de puntos de control; Inmunoterapia Càncer cervical; Inhibidor de punts de control; Immunoteràpia Objective This phase II clinical trial evaluated the safety
Autor:
Breelyn Wilky, Anthony El-Khoueiry, Andrea Bullock, Apostolia Tsimberidou, Daruka Mahadevan, Kim Margolin, Jonathan Trent, Bruno Bockorny, Justin Moser, Peter Hosein, Marwan Fakih, Benjamin Schlecter, Jacob Thomas, Ani Balmanoukian, Rachel Sanborn, Ghassan Abou-Alfa, Gary Schwartz, Diana Hanna, Waldo Ortuzar Feliu, Joseph Grossman, Katherine Rosenthal, James Godwin, Jaymin Patel, Bonnie Bullock, Justin Stebbing, Bhupendra Rawal, Hunter Cole, Chloe Delepine, Jacky Chow, Ross Walker, Chris MacDermaid, Dhan Chand, Michael Gordon, Heinz-Josef Lenz, Steven O’Day
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Marco Purbhoo, Burcu Yigit, Xavier Michelet, Rachel Smith, Darrian Moskowitz, Maurice Kirby, Alexa Buffa, Sonia De Munari, Waldo Ortuzar Feliu, Koen Van Besien, Don Stevens, Mark Exley, Terese Hammond
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Robert L. Coleman, Marek Ancukiewicz, R. Wendel Naumann, Bradley J. Monk, Kathleen N. Moore, Krishnansu S. Tewari, Leslie M Randall, Waldo Ortuzar Feliu, Brian M. Slomovitz, Camille Gunderson Jackson, David M. O'Malley, Rodney P. Rocconi, John L. Hays
Publikováno v:
Future oncology (London, England). 17(26)
Balstilimab (anti-programmed death 1) and zalifrelimab (anti-CTLA-4) are two new checkpoint inhibitors that have emerged as promising investigational agents for the treatment of cervical cancer, particularly in the setting of previously-treated, recu
Autor:
Remigiusz Kaleta, Madhavi Nallewar, Robert Ludwig, Michael O'Neal, Waldo Ortuzar Feliu, Jennifer Buell, David M. O'Malley, Jérôme Alexandre, Anna Wijatyk, Victoria Borisovskaya, Julie Cole, Isabelle Ray-Coquard
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background The phenomenon of pseudoprogression (PsP) may appear with cancer immunotherapy. The underlying etiology is not fully elucidated, tumor flare is the suspected mechanism of early pseudoprogression that may resolve gradually while continuing
Autor:
Robert Wesolowski, Remigiusz Kaleta, Waldo Ortuzar Feliu, Hong Zhang, Breelyn A. Wilky, Anna Wijatyk, Irina M. Shapiro, Jonathan C. Trent, Cesar A. Perez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Zalifrelimab is a fully human monoclonal antibody against cytotoxic T-lymphocyte -associated protein 4 (CTLA-4). Preliminary data demonstrated clinical benefit and tolerability, as monotherapy, in patients with recurrent solid tumors inclu